Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
| Autor: | Sailaja Puttagunta, Michael W. Dunne, Karthik Akinapelli, Pedro L Gonzalez, Urania Rappo, Jennifer S McGregor |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty infectious disease 030106 microbiology Population Skin infection methicillin-resistant Staphylococcus aureus staphylococcal 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Clinical endpoint substance abuse 030212 general & internal medicine Adverse effect education Original Research Pharmacology education.field_of_study skin infection Skin and skin structure infection business.industry lcsh:RM1-950 Dalbavancin General Medicine medicine.disease Clinical trial Regimen lcsh:Therapeutics. Pharmacology intravenous Molecular Medicine business dalbavancin |
| Zdroj: | Drugs in Context, Vol 7, Pp 1-10 (2018) Drugs in Context |
| ISSN: | 1740-4398 |
| Popis: | Background Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, complicate the medical care of the PWID population, adversely affecting patient outcomes. Methods We assessed demographics and outcomes for the PWID population in a double-blind trial of 698 patients randomized to dalbavancin 1500 mg as a single intravenous (IV) infusion or as a 2-dose regimen (1000 mg IV on day 1; 500 mg IV on day 8) for ABSSSI. The primary endpoint was ≥20% reduction in erythema at 48-72 hours in the intent-to-treat population; clinical status was also assessed at days 14 and 28. Results There were 212/698 (30.4%) patients with a history of injection drug use in this clinical trial. Dalbavancin efficacy was similar between the single- and 2-dose therapy groups in the PWID and non-PWID populations at all timepoints. Dalbavancin was well tolerated in the PWID population, with similar rates of adverse events as the non-PWID population. Conclusion Dalbavancin as a single-dose or 2-dose regimen had similar efficacy for the treatment of ABSSSI at all timepoints in the PWID and non-PWID populations. A single 30-minute IV infusion would eliminate the need for indwelling IV access. The convenience of a single dose supervised in a health setting may also optimize treatment adherence in the PWID population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|